You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Evaluation (II)1 Apr 20131398 ORGASM PROFILES IN MEN ON ANDROGEN DEPRIVATION THERAPY (ADT) FOR PROSTATE CANCER Patrick Teloken, Clarisse R. Mazzola, and John P. Mulhall Patrick TelokenPatrick Teloken New York City, NY More articles by this author , Clarisse R. MazzolaClarisse R. Mazzola New York City, NY More articles by this author , and John P. MulhallJohn P. Mulhall New York City, NY More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2752AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES ADT is a recognized management strategy for prostate cancer. ADT is associated with numerous sexual function sequelae, including erectile dysfunction and loss of libido. Little attention has been paid to orgasm function in such patients. This analysis evaluated orgasm profiles in these patients. METHODS All patients presenting to our sexual medicine clinic are interviewed in a comprehensive fashion regarding erection, ejaculation, orgasm, libido and penile morphology. To be included in the analysis, patients needed (i) to have residual libido (ii) to be sexually active (iii) to be seen within 6 months of commencing treatment. With regard to orgasm, questions were asked regarding its presence with partner of with self-stimulation, its nature, ease of achievement, associated pain or urinary leakage. Patient demographic and prostate cancer data were also recorded. RESULTS 112 men were included in the study with mean age = 68±11 years. 86% were partnered. All had pre-ADT orgasm with their partner. 102/112 had prior radical prostatectomy or prostate radiation. 89/102 were using ADT as a salvage therapy (PSA elevation), the remainder as adjuvant therapy for high risk disease. 72 were capable of sexual intercourse (68 on intracavernosal injections, 4 using a penile implant). Mean libido level = 5±3 (on 10 point scale). Mean sexual activity frequency = 1±1.2/month (0.5-4). 13/112 (12%) experienced orgasm on at least one occasion but with time all lost this ability. Mean time to complete loss of orgasm = 5±2.5 months on ADT, with 12% capable of orgasm within 6 months of starting ADT, 8% 6-12 months and none beyond that time-point. Of the 13 men with orgasm, all declared a significant reduction in orgasmic intensity and significant prolongation of intravaginal ejaculatory latency time (IELT). 76 patients had IIEF question 10 data. Mean scores were 1.8±0.6 at ≤6 months on ADT, 0.9±0.6 at 6-12 months, and 0 after that. CONCLUSIONS ADT results in significant orgasm dysfunction with loss of orgasmic capability in all patients with time and reduced intensity and increased IELT in all. Patients undergoing ADT should be counseled regarding changes in orgasm. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e572 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Patrick Teloken New York City, NY More articles by this author Clarisse R. Mazzola New York City, NY More articles by this author John P. Mulhall New York City, NY More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Read full abstract